# Testing the Efficacy and Safety of BIO101 for the Prevention of Respiratory Deterioration in COVID-19 Patients

> **NCT04472728** · PHASE2,PHASE3 · TERMINATED · sponsor: **Biophytis** · enrollment: 238 (actual)

## Conditions studied

- Covid-19
- SARS-CoV2

## Interventions

- **DRUG:** BIO101
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04472728
- **Lead sponsor:** Biophytis
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-08-26
- **Primary completion:** 2022-06-06
- **Final completion:** 2022-09-30
- **Target enrollment:** 238 (ACTUAL)
- **Why stopped:** Lack of eligible patients due to lower number of Covid-19 cases in all involved sites.
- **Last updated:** 2023-05-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04472728

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04472728, "Testing the Efficacy and Safety of BIO101 for the Prevention of Respiratory Deterioration in COVID-19 Patients". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04472728. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*